文献速递乳腺外科

基于基因表达谱的检测预测黑色素瘤前哨淋巴结状态:MERLIN_001研究

Gene Expression Profile-Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 Study.
PubMed 文献 · JAMA Surg · 2025-01-01

这项多中心前瞻性盲法预后研究在1761例T1-T3期临床淋巴结阴性黑色素瘤患者中评估CP-GEP检测预测前哨淋巴结活检(SLNB)阴性的能力。37.0%患者被CP-GEP判为低危,其前哨淋巴结阳性率为7.1%,阴性预测值为92.9%(95%CI 90.7%-94.8%)。研究结论认为CP-GEP可可靠识别前哨淋巴结转移风险低于10%的患者。

要点

  • CP-GEP低危患者前哨淋巴结阳性率7.1%,阴性预测值92.9%。
  • 低危比例随T分期升高而下降:T1为68.2%,T2为32.9%,T3为2.8%。
  • 高危患者前哨淋巴结阳性率23.8%,约为低危患者的3倍。

核心结论

  • CP-GEP检测可可靠识别前哨淋巴结转移风险低于10%的黑色素瘤患者。
  • 高危与低危CP-GEP病例的前哨淋巴结转移率相差约3倍。
  • 在合适选择的患者中,CP-GEP检测可能为医患共同决策增加价值。

研究设计与样本

  • 多中心、前瞻性、盲法预后研究,2021年9月至2024年6月在9家学术医学中心开展。
  • 纳入活检证实的T1至T3期侵袭性皮肤黑色素瘤且临床区域淋巴结阴性、按标准临床标准适合SLNB的患者。
  • 共1761例患者接受SLNB并成功完成CP-GEP检测,中位年龄64岁(IQR 53-72),男性997例(56.6%)。
  • GEP在石蜡包埋原发黑色素瘤活检组织上进行,样本检测成功率为97.7%。

主要发现

  • 310例(17.6%)SLN阳性;651例(37.0%)被CP-GEP判为低危。
  • 低危病例中46例(7.1%)SLN阳性,阴性预测值为92.9%(95%CI 90.7%-94.8%)。
  • 高危病例SLN阳性率为23.8%(264/1110)。
  • 低危CP-GEP比例随T分期升高而下降:T1为346/507(68.2%),T2为295/897(32.9%),T3为10/357(2.8%)。
  • 临床IB期低危病例SLN阳性率为6.5%(95%CI 4.6%-8.8%),65岁及以上低危病例为6.6%(95%CI 4.2%-9.7%),对应高危病例分别为18.3%(95%CI 15.3%-21.6%)和20.3%(95%CI 16.8%-24.2%)。

关键数值与推荐

  • 现行指南推荐对预测SLN转移风险大于10%的黑色素瘤患者行SLNB,风险5%至10%时考虑SLNB。
  • CP-GEP结果分为低危和高危,主要结局指标为低危病例的阴性预测值。

临床怎么用

  • CP-GEP检测可辅助识别可安全免除SLNB的低危黑色素瘤患者。
  • CP-GEP结果可结合T分期、原发部位和年龄等信息用于医患共同决策。

局限性

  • 原文未报告CP-GEP对前哨淋巴结阴性患者结局的预后价值。
  • 研究纳入的是按标准临床标准适合SLNB的患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Contemporary guidelines recommend sentinel lymph node biopsy (SLNB) for patients with melanoma with predicted risk of SLN metastasis greater than 10% and consideration of SLNB when the risk is 5% to 10%. A gene expression profile (GEP)-based test that can accurately identify patients with a low risk of SLN metastasis would refine selection for SLNB. OBJECTIVE: To establish the predictive capability of the combined clinicopathological factors and GEP (CP-GEP) test to identify patients with primary cutaneous melanoma who can safely forgo SLNB and to investigate the prognostic value of CP-GEP regarding the outcome in patients with cutaneous melanoma after a negative SLNB (not reported herein). DESIGN, SETTING, AND PARTICIPANTS: This prognostic study was conducted from September 2021 to June 2024 at 9 academic medical centers with experienced melanoma surgeons. Included were patients with biopsy-proven invasive cutaneous melanoma with T1 to T3 tumors and clinically negative regional LNs. All patients were deemed candidates for SLNB using standard clinical criteria. GEP was performed on formalin-fixed, paraffin-embedded tissue from the primary melanoma biopsy. Analyses were performed from December 2024 to August 2025. INTERVENTION: CP-GEP testing to determine risk of having a positive SLNB in patients with T1 to T3 cutaneous melanoma who were considered appropriate candidates for the procedure based on standard clinical parameters. MAIN OUTCOMES AND MEASURES: CP-GEP results were reported as low risk or high risk; the primary outcome measure was negative predictive value (NPV) in low-risk cases. Analyses included NPV assessment by tumor (T) subcategory, primary site, and age. RESULTS: A total of 1761 patients (median [IQR] age, 64 [53-72] years; 997 male [56.6%]) underwent SLNB (310 [17.6%] SLN positive) and had a successful CP-GEP test; GEP was successful in 97.7% of samples. A total of 651 patients (37.0%) were considered low risk by CP-GEP. Among low-risk cases, 46 (7.1%) were SLN positive, and NPV was 92.9% (95% CI, 90.7%-94.8%). High-risk cases had a 23.8% (264 of 1110) SLN-positive rate. The percentage of cases with low-risk CP-GEP declined with increasing T category (T1 = 346 of 507 [68.2%]; T2 = 295 of 897 [32.9%]; T3 = 10 of 357 [2.8%]). CP-GEP results were consistent in discriminating SLN-positive rates across primary sites, histologic subtypes, and mitotic count categories. In 2 large subsets, clinical stage IB (n = 1187) and patients 65 years and older (n = 832), 6.5% (95% CI, 4.6%-8.8%) of low-risk clinical stage IB cases and 6.6% (95% CI, 4.2%-9.7%) of all low-risk cases in patients 65 years and older were SLN positive vs 18.3% (95% CI, 15.3%-21.6%) and 20.3% (95% CI, 16.8%-24.2%) for high-risk cases, respectively. CONCLUSIONS AND RELEVANCE: In this multicenter, prospective, blinded, prognostic study, the CP-GEP test reliably identified patients with melanoma with less than 10% SLN metastasis risk. SLN metastasis rates were approximately 3-fold greater for high-risk vs low-risk CP-GEP cases. In appropriately selected patients, the CP-GEP test may add value for shared patient-surgeon decision-making.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Hieken TJ, Egger ME, Angeles CV, et al. Gene Expression Profile-Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 Study. JAMA Surg. 2025. PMID: 41123931. doi:10.1001/jamasurg.2025.4399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。